Young-Guk Ko

Young-Guk Ko

Auto-generated profile, based on publicly available information

Young-Guk Ko

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2015 in JAMA
Verified
Journal Article
Open access
PDF file
SHSung-Jin Hong
Sung-Jin Hong
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
DSDong-Ho Shin
Dong-Ho Shin
CNChung Mo Nam
Chung Mo Nam
Jung Sun KimJung Sun Kim
Jung Sun Kim
FIfor the IVUS-XPL Investigators
for the IVUS-XPL Investigators
The introduction of the drug-eluting stent (DES) has contributed to a significant reduction in in-stent restenosis and repeat revascularization.1,2 However, despite the use of the DES, percutaneous coronary intervention (PCI) of diffuse long coronary lesions still remains challenging because the prevalence of in-stent restenosis and stent thrombosis remains high compared with short-length coronary lesions.3,4

1 October 2012 in JACC
Verified
Journal Article
Closed access
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
MHMyeong-Ki Hong
Myeong-Ki Hong
DSDong-Ho Shin
Dong-Ho Shin
CNChung Mo Nam
Chung Mo Nam
Jung Sun KimJung Sun Kim
Jung Sun Kim
YJYangsoo Jang
Yangsoo Jang

1 January 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SHSung-Jin Hong
Sung-Jin Hong
GMGary S. Mintz
Gary S. Mintz
CAChul-Min Ahn
Chul-Min Ahn
Jung Sun KimJung Sun Kim
Jung Sun Kim
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
MHMyeong-Ki Hong
Myeong-Ki Hong

1 November 2004 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
DCDonghoon Choi
Donghoon Choi
SKSoo-Kyung Kim
Soo-Kyung Kim
SCSung-Hee Choi
Sung-Hee Choi
YKYoung-Guk Ko
Young-Guk Ko
CAChul Woo Ahn
Chul Woo Ahn
BCBong-Soo Cha
Bong-Soo Cha
OBJECTIVE—Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS—We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS—Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4% vs. 40.9 ± 31.9%, P = 0.004) compared with the control group. CONCLUSIONS—We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.

1 April 2013 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Jung Sun KimJung Sun Kim
Jung Sun Kim
TKTae-Soo Kang
Tae-Soo Kang
GMGary S. Mintz
Gary S. Mintz
BPByoung-Eun Park
Byoung-Eun Park
DSDong-Ho Shin
Dong-Ho Shin
MHMyeong-Ki Hong
Myeong-Ki Hong

20 February 2024 in Circulation
Verified
Journal Article
Closed access
SHSung-Jin Hong
Sung-Jin Hong
JLJun-Won Lee
Jun-Won Lee
YSYongsung Suh
Yongsung Suh
KYKyeong Ho Yun
Kyeong Ho Yun
TKTae Soo Kang
Tae Soo Kang
OIon behalf of the T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators
on behalf of the T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators
BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome. METHODS: In this randomized, open-label, noninferiority trial, 2850 patients with acute coronary syndrome who underwent drug-eluting stent implantation at 24 centers in South Korea were randomly assigned (1:1) to receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424) between April 24, 2019, and May 31, 2022. The primary end point was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. Key secondary end points were the individual components of the primary end point. RESULTS: Among 2850 patients who were randomized (mean age, 61 years; 40% ST-segment–elevation myocardial infarction), 2823 (99.0%) completed the trial. Aspirin was discontinued at a median of 16 days (interquartile range, 12–25 days) in the group receiving ticagrelor monotherapy after <1 month of DAPT. The primary end point occurred in 40 patients (2.8%) in the group receiving ticagrelor monotherapy after <1-month DAPT, and in 73 patients (5.2%) in the ticagrelor-based 12-month DAPT group (hazard ratio, 0.54 [95% CI, 0.37–0.80]; P <0.001 for noninferiority; P =0.002 for superiority). This finding was consistent in the per-protocol population as a sensitivity analysis. The occurrence of major bleeding was significantly lower in the ticagrelor monotherapy after <1-month DAPT group compared with the 12-month DAPT group (1.2% versus 3.4%; hazard ratio, 0.35 [95% CI, 0.20–0.61]; P <0.001). CONCLUSIONS: This study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both noninferior and superior to 12-month DAPT for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding, primarily because of a significant reduction in major bleeding, among patients with acute coronary syndrome receiving drug-eluting stent implantation. Low event rates, which may suggest enrollment of relatively non–high-risk patients, should be considered in interpreting the trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03797651.